Speaker: Jacqueline Cloos

0:00:52

The importance of evaluating heterogeneity in AML and how this may impact MRD assessment

0:02:04

Novel techniques being used for MRD assessment in AML & the importance of considering oligoclonality

0:01:42

Implementing MRD in clinical practice for patients with intermediate-risk AML

0:01:20

The prognostic value of CD34+CD38- leukemic stem cell frequency in AML

0:01:47

Flow identification and monitoring of leukemia stem cells

0:01:35

The role of MRD in AML

0:03:37

The future of AML treatment

0:01:40

SF3B1 as therapeutic target in FLT3/ITD positive AML

0:02:35

Molecular diagnosis and MRD monitoring in AML

0:00:13

STOP 🛑 Getting Up Like THIS In Pregnancy! #shorts #pregnancy

0:00:57

How to Check AML Risk of Your Own or Someone Else's TON Chain Wallet Adress Tutorial

0:03:41

MRD-guided therapy in patients with intermediate-risk AML compared to unguided cohort using PSM

0:04:20

Super sunglasses at cheap rates